中国2025年1月1日生效的《2025年清单》中增加了七种新药,包括一种新的子宫颈癌治疗。 Seven Innovent drugs, including a new endometrial cancer treatment, added to China’s 2025医保 list, effective Jan. 1, 2026.

七种创新生物药物,包括TYVYT和中国首种IGF-1R抗体SYCUME的子宫内癌症新指标,已被列入2025年中国国家退款药物清单,自2026年1月1日起生效。 Seven Innovent Biologics drugs, including a new endometrial cancer indication for TYVYT and China’s first IGF-1R antibody SYCUME, have been added to China’s 2025 National Reimbursement Drug List, effective January 1, 2026. 其中包括扩大获得多种癌症、甲状腺眼病和其他严重病症治疗的机会,几种药物针对肺癌和血液恶性肿瘤中的特定基因突变。 The inclusion expands access to treatments for multiple cancers, thyroid eye disease, and other serious conditions, with several drugs targeting specific genetic mutations in lung cancer and hematologic malignancies. 该举措旨在提高中国各地创新疗法的可负担性和可用性。 The move aims to improve affordability and availability of innovative therapies across China.